NASDAQ:ALEC   Alector, Inc.
The safety data is favorable and biomarker/clinical data of AL001 (latozinemab) is supportive of activity in this expanded group of patients. Today's data also suggests the potential for a treatment effect in other TDP pathologies (such as ALS).


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.